International pivotal phase III trial of liposomal paclitaxel [EndoTag-1] in patients with triple-negative breast cancer.

Trial Profile

International pivotal phase III trial of liposomal paclitaxel [EndoTag-1] in patients with triple-negative breast cancer.

Not yet recruiting
Phase of Trial: Phase III

Latest Information Update: 27 May 2013

At a glance

  • Drugs Paclitaxel (Primary)
  • Indications Breast cancer
  • Focus Registrational; Therapeutic Use
  • Most Recent Events

    • 27 May 2013 This trial is expected to start in the second half of 2014, according to a media release from SynCore Biotechnology and MediGene.
    • 27 May 2013 Status changed from planning to not yet recruiting, as reported in a media release from SynCore Biotechnology and MediGene.
    • 13 Jul 2012 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top